Skip to main content
Erschienen in: Journal of Endocrinological Investigation 5/2022

01.05.2022 | Original Article

Serum alpha-melanocyte-stimulating hormone (a-MSH), brain-derived neurotrophic factor (BDNF), and agouti-related protein (AGRP) levels in children with Prader-Willi or Bardet-Biedl syndromes

verfasst von: D. Turkkahraman, E. C. Sirazi, G. Aykal

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Although leptin/melanocortin pathway pathologies in hypothalamus are thought to be the main cause of early-onset obesity and hyperphagia in PWS and BBS, the exact mechanism is still not known.

Objective

To measure serum concentrations of a-MSH, BDNF and AGRP in a group of children with BBS or PWS.

Methods

We recruited 12 subjects with PWS, 12 subjects with BBS, 28 obese controls (OC) and 26 lean controls (LC) matched for age, sex and puberty. Serum a-MSH, BDNF and AGRP levels were measured by the ELISA method.

Results

The mean a-MSH level was lower in PWS than those of OC and LC (3729 ± 1319, 5211 ± 829 and 5681 ± 565 pg/ml, respectively, p < 0.001), and mean a-MSH was lower in OC than LC (p < 0.05). The mean BDNF level of PWS was higher than those of OC and LC (565 ± 122, 482 ± 102 and 391 ± 74 pg/ml, respectively, p < 0.001). On the other hand, mean a-MSH level of BBS was lower than those of OC and LC (4543 ± 658, 5211 ± 829 and 5681 ± 565 pg/ml, respectively, p < 0.001), and mean a-MSH was lower in OC than LC (p < 0.05). The mean BDNF level of BBS was higher than those of OC and LC (583 ± 115, 482 ± 102 and 391 ± 74 pg/ml, respectively, p < 0.001). Additionally, both in PWS and BBS, the mean BDNF level was higher in OC than LC (p < 0.01). Regarding AGRP level, there was no difference both in BBS and PWS compared to OC.

Conclusion

We found that the serum a-MSH levels of PWS and BBS groups are significantly lower compared to those of obese and lean controls. Therefore, we can speculate that the circulating a-MSH level does properly reflect its central production, and the serum a-MSH level might be a good biomarker to detect a-MSH deficiency in individuals suspected to have BBS or PWS, and also in those with POMC, PCSK1, and LEPR deficiency.
Literatur
1.
Zurück zum Zitat Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14(1):10–26CrossRef Cassidy SB, Schwartz S, Miller JL, Driscoll DJ (2012) Prader-Willi syndrome. Genet Med 14(1):10–26CrossRef
2.
Zurück zum Zitat Angulo MA, Butler MG, Cataletto ME (2015) Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 38:1249–1263CrossRef Angulo MA, Butler MG, Cataletto ME (2015) Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 38:1249–1263CrossRef
3.
Zurück zum Zitat Forsythe E, Beales PL (2013) Bardet-Biedl syndrome. Eur J Hum Genet 21(1):8–13CrossRef Forsythe E, Beales PL (2013) Bardet-Biedl syndrome. Eur J Hum Genet 21(1):8–13CrossRef
4.
Zurück zum Zitat Kenny J, Forsythe E, Beales P, Bacchelli C (2017) Toward personalized medicine in Bardet-Biedl syndrome. Per Med 14(5):447–456CrossRef Kenny J, Forsythe E, Beales P, Bacchelli C (2017) Toward personalized medicine in Bardet-Biedl syndrome. Per Med 14(5):447–456CrossRef
5.
Zurück zum Zitat Best S, Lord J, Roche M, Watson CM, Poulter JA, Bevers RPJ, et al. Molecular diagnoses in the congenital malformations caused by ciliopathies cohort of the 100,000 Genomes Project. J Med Genet. 2021; 29: jmedgenet-2021–108065. Best S, Lord J, Roche M, Watson CM, Poulter JA, Bevers RPJ, et al. Molecular diagnoses in the congenital malformations caused by ciliopathies cohort of the 100,000 Genomes Project. J Med Genet. 2021; 29: jmedgenet-2021–108065.
6.
Zurück zum Zitat Baldini G, Phelan KD (2019) The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol 241:1–33CrossRef Baldini G, Phelan KD (2019) The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol 241:1–33CrossRef
7.
Zurück zum Zitat Ramos-Molina B, Molina-Vega M, Fernández-García JC, Creemers JW. Hyperphagia and Obesity in Prader-Willi Syndrome: PCSK1 Deficiency and Beyond? Genes (Basel). 2018; 7;9(6):288–297. Ramos-Molina B, Molina-Vega M, Fernández-García JC, Creemers JW. Hyperphagia and Obesity in Prader-Willi Syndrome: PCSK1 Deficiency and Beyond? Genes (Basel). 2018; 7;9(6):288–297.
8.
Zurück zum Zitat Feuillan PP, Ng D, Han JC, Sapp JC, Wetsch K, Spaulding E (2011) Patients with Bardet-Biedl syndrome have hyperleptinemia suggestive of leptin resistance. J Clin Endocrinol Metab 96(3):528–535CrossRef Feuillan PP, Ng D, Han JC, Sapp JC, Wetsch K, Spaulding E (2011) Patients with Bardet-Biedl syndrome have hyperleptinemia suggestive of leptin resistance. J Clin Endocrinol Metab 96(3):528–535CrossRef
9.
Zurück zum Zitat Han JC, Muehlbauer MJ, Cui HN, Newgard CB, Haqq AM (2010) Lower Brain-Derived Neurotrophic Factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab 95(7):3532–3536CrossRef Han JC, Muehlbauer MJ, Cui HN, Newgard CB, Haqq AM (2010) Lower Brain-Derived Neurotrophic Factor in patients with Prader-Willi syndrome compared to obese and lean control subjects. J Clin Endocrinol Metab 95(7):3532–3536CrossRef
10.
Zurück zum Zitat Bueno M, Esteba-Castillo S, Novell R, Gimenez-Palop O, Coronas R, Gabau E, et al. Lack of postprandial peak in brain-derived neurotrophic factor in adults with Prader- Willi syndrome. PLoS One. 2016; 11(9): e0163468 Bueno M, Esteba-Castillo S, Novell R, Gimenez-Palop O, Coronas R, Gabau E, et al. Lack of postprandial peak in brain-derived neurotrophic factor in adults with Prader- Willi syndrome. PLoS One. 2016; 11(9): e0163468
11.
Zurück zum Zitat Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA (1999) New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet 36:437–446PubMedPubMedCentralCrossRef Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA (1999) New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet 36:437–446PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Neyzi O, Bundak R, Gokcay G, Gunoz H, Furman A, Darendeliler F et al (2015) Reference values for weight, height, head circumference and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7(4):280–293CrossRef Neyzi O, Bundak R, Gokcay G, Gunoz H, Furman A, Darendeliler F et al (2015) Reference values for weight, height, head circumference and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7(4):280–293CrossRef
13.
Zurück zum Zitat Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44(235):291–303CrossRef Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44(235):291–303CrossRef
14.
Zurück zum Zitat Goldstone AP, Holland AJ, Butler JV, Whittington JE (2012) Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obese 36(12):1564–1570CrossRef Goldstone AP, Holland AJ, Butler JV, Whittington JE (2012) Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obese 36(12):1564–1570CrossRef
15.
Zurück zum Zitat Butler MG, Moore J, Morawiecki A, Nicolson M (1998) Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet 75:7–12CrossRef Butler MG, Moore J, Morawiecki A, Nicolson M (1998) Comparison of leptin protein levels in Prader-Willi syndrome and control individuals. Am J Med Genet 75:7–12CrossRef
16.
Zurück zum Zitat Kweh FA, Miller JL, Sulsona CR et al (2015) Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A 167:69–79CrossRef Kweh FA, Miller JL, Sulsona CR et al (2015) Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. Am J Med Genet A 167:69–79CrossRef
17.
Zurück zum Zitat Muscogiuri G, Barrea L, Faggiano F, Maiorino MI, Parrillo M, Pugliese G et al (2021) Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest 44:2057–2070CrossRef Muscogiuri G, Barrea L, Faggiano F, Maiorino MI, Parrillo M, Pugliese G et al (2021) Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest 44:2057–2070CrossRef
18.
Zurück zum Zitat Irizarry KA, Miller M, Freemark M, Haqq AM (2016) Prader Willi Syndrome; genetics, metabolomics, hormonal Function, and new approaches to therapy. Adv Pediatr 63(1):47–77CrossRef Irizarry KA, Miller M, Freemark M, Haqq AM (2016) Prader Willi Syndrome; genetics, metabolomics, hormonal Function, and new approaches to therapy. Adv Pediatr 63(1):47–77CrossRef
19.
Zurück zum Zitat Guo D-F, Lin Z, Yuanming Wu, Searby C, Thedens DR, Richerson GB et al (2019) The BBSome in POMC and AgRP neurons is necessary for body weight regulation and sorting of metabolic receptors. Diabetes 68(8):1591–1603CrossRef Guo D-F, Lin Z, Yuanming Wu, Searby C, Thedens DR, Richerson GB et al (2019) The BBSome in POMC and AgRP neurons is necessary for body weight regulation and sorting of metabolic receptors. Diabetes 68(8):1591–1603CrossRef
20.
Zurück zum Zitat Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H et al (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 8(12):960–970CrossRef Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H et al (2020) Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 8(12):960–970CrossRef
21.
Zurück zum Zitat Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G et al (2020) Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 22(11):2133–2140CrossRef Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G et al (2020) Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 22(11):2133–2140CrossRef
22.
Zurück zum Zitat Poitou C, Mosbah H, Clément K (2020) MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity. Eur J Endocrinol 183(5):149–166CrossRef Poitou C, Mosbah H, Clément K (2020) MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity. Eur J Endocrinol 183(5):149–166CrossRef
23.
Zurück zum Zitat Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR et al (2012) Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med 18:564–571CrossRef Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR et al (2012) Dendritically targeted Bdnf mRNA is essential for energy balance and response to leptin. Nat Med 18:564–571CrossRef
24.
Zurück zum Zitat Gray J, Yeo GSH, Cox JJ et al (2006) Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF). Gene Diabetes 55:3366–3371CrossRef Gray J, Yeo GSH, Cox JJ et al (2006) Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF). Gene Diabetes 55:3366–3371CrossRef
25.
Zurück zum Zitat Yeo GS, Connie Hung CC, Rochford J et al (2004) A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7:1187–1189CrossRef Yeo GS, Connie Hung CC, Rochford J et al (2004) A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7:1187–1189CrossRef
26.
Zurück zum Zitat Bochukova EG, Lawler K, Croizier S, Keogh JM, Patel N, Strohbehn G et al (2018) A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader- Willi syndrome. Cell Rep 22(13):3401–3408CrossRef Bochukova EG, Lawler K, Croizier S, Keogh JM, Patel N, Strohbehn G et al (2018) A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader- Willi syndrome. Cell Rep 22(13):3401–3408CrossRef
27.
Zurück zum Zitat Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: Data from the Baltimore longitudinal study of aging. PLoS ONE. 2010; 5: e10099. Golden E, Emiliano A, Maudsley S, Windham BG, Carlson OD, Egan JM, et al. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: Data from the Baltimore longitudinal study of aging. PLoS ONE. 2010; 5: e10099.
28.
Zurück zum Zitat Slusher AL, Whitehurst M, Zoeller RF, Mock JT, Maharaj A, Huang CJ (2015) Brain-derived neurotrophic factor and substrate utilization following acute aerobic exercise in obese individuals. J Neuroendocrinol 27:370–376CrossRef Slusher AL, Whitehurst M, Zoeller RF, Mock JT, Maharaj A, Huang CJ (2015) Brain-derived neurotrophic factor and substrate utilization following acute aerobic exercise in obese individuals. J Neuroendocrinol 27:370–376CrossRef
29.
Zurück zum Zitat Sandrini L, Minno AD, Amadio P, Ieraci A, Tremoli E, Barbieri SS (2018) Association between obesity and circulating brain-derived neurotrophic factor (BDNF) levels: systematic review of literature and meta-analysis. Int J Mol Sc 19:2281CrossRef Sandrini L, Minno AD, Amadio P, Ieraci A, Tremoli E, Barbieri SS (2018) Association between obesity and circulating brain-derived neurotrophic factor (BDNF) levels: systematic review of literature and meta-analysis. Int J Mol Sc 19:2281CrossRef
30.
Zurück zum Zitat Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN et al (2000) Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470(2):113–117CrossRef Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN et al (2000) Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470(2):113–117CrossRef
31.
Zurück zum Zitat Amadio P, Baldassarre D, Sandrini L, Weksler BB, Tremoli E, Barbieri SS (2017) Effect of cigarette smoke on monocyte procoagulant activity: Focus on platelet-derived brain-derived neurotrophic factor (BDNF). Platelets 28:60–65CrossRef Amadio P, Baldassarre D, Sandrini L, Weksler BB, Tremoli E, Barbieri SS (2017) Effect of cigarette smoke on monocyte procoagulant activity: Focus on platelet-derived brain-derived neurotrophic factor (BDNF). Platelets 28:60–65CrossRef
Metadaten
Titel
Serum alpha-melanocyte-stimulating hormone (a-MSH), brain-derived neurotrophic factor (BDNF), and agouti-related protein (AGRP) levels in children with Prader-Willi or Bardet-Biedl syndromes
verfasst von
D. Turkkahraman
E. C. Sirazi
G. Aykal
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 5/2022
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-021-01737-8

Weitere Artikel der Ausgabe 5/2022

Journal of Endocrinological Investigation 5/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.